ID   FANCJ_HUMAN             Reviewed;        1249 AA.
AC   Q9BX63; A0A024QZ45; Q3MJE2; Q8NCI5;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   10-OCT-2018, sequence version 2.
DT   28-JUN-2023, entry version 191.
DE   RecName: Full=Fanconi anemia group J protein {ECO:0000305};
DE            Short=Protein FACJ;
DE            EC=3.6.4.13 {ECO:0000269|PubMed:20639400};
DE   AltName: Full=ATP-dependent RNA helicase BRIP1;
DE   AltName: Full=BRCA1-associated C-terminal helicase 1;
DE   AltName: Full=BRCA1-interacting protein C-terminal helicase 1;
DE            Short=BRCA1-interacting protein 1;
GN   Name=BRIP1 {ECO:0000312|HGNC:HGNC:20473}; Synonyms=BACH1, FANCJ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 708-747;
RP   765-790; 815-831; 1079-1085; 1169-1174 AND 1215-1225, FUNCTION, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, INTERACTION WITH BRCA1, MUTAGENESIS OF
RP   LYS-52, VARIANTS BC ALA-47 AND ILE-299, VARIANTS ILE-193 AND PRO-919, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11301010; DOI=10.1016/s0092-8674(01)00304-x;
RA   Cantor S.B., Bell D.W., Ganesan S., Kass E.M., Drapkin R., Grossman S.,
RA   Wahrer D.C.R., Sgroi D.C., Lane W.S., Haber D.A., Livingston D.M.;
RT   "BACH1, a novel helicase-like protein, interacts directly with BRCA1 and
RT   contributes to its DNA repair function.";
RL   Cell 105:149-160(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-919.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1249 (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   PHOSPHORYLATION AT SER-990, AND MUTAGENESIS OF SER-986; SER-988; THR-989;
RP   SER-990; PRO-991; THR-992; PHE-993; THR-997; SER-1001; SER-1003; SER-1004;
RP   SER-1007; TYR-1011 AND THR-1013.
RX   PubMed=14576433; DOI=10.1126/science.1088753;
RA   Yu X., Chini C.C.S., He M., Mer G., Chen J.;
RT   "The BRCT domain is a phospho-protein binding domain.";
RL   Science 302:639-642(2003).
RN   [7]
RP   FUNCTION, MUTAGENESIS OF LYS-52, AND CHARACTERIZATION OF VARIANTS BC ALA-47
RP   AND ILE-299.
RX   PubMed=14983014; DOI=10.1073/pnas.0308717101;
RA   Cantor S.B., Drapkin R., Zhang F., Lin Y., Han J., Pamidi S.,
RA   Livingston D.M.;
RT   "The BRCA1-associated protein BACH1 is a DNA helicase targeted by
RT   clinically relevant inactivating mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2357-2362(2004).
RN   [8]
RP   FUNCTION, VARIANT PRO-919, AND DISEASE.
RX   PubMed=16153896; DOI=10.1016/j.ccr.2005.08.004;
RA   Litman R., Peng M., Jin Z., Zhang F., Zhang J., Powell S., Andreassen P.R.,
RA   Cantor S.B.;
RT   "BACH1 is critical for homologous recombination and appears to be the
RT   Fanconi anemia gene product FANCJ.";
RL   Cancer Cell 8:255-265(2005).
RN   [9]
RP   FUNCTION, MUTAGENESIS OF LYS-52, AND DISEASE.
RX   PubMed=16116421; DOI=10.1038/ng1627;
RA   Bridge W.L., Vandenberg C.J., Franklin R.J., Hiom K.;
RT   "The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia
RT   pathway for DNA crosslink repair.";
RL   Nat. Genet. 37:953-957(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-927; SER-930 AND SER-990, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-930 AND SER-1032, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1237, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   ACETYLATION AT LYS-1249.
RX   PubMed=22792074; DOI=10.1371/journal.pgen.1002786;
RA   Xie J., Peng M., Guillemette S., Quan S., Maniatis S., Wu Y., Venkatesh A.,
RA   Shaffer S.A., Brosh R.M. Jr., Cantor S.B.;
RT   "FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage
RT   response.";
RL   PLoS Genet. 8:E1002786-E1002786(2012).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CIAO1; CIAO2B AND MMS19.
RX   PubMed=23585563; DOI=10.1074/jbc.m112.416602;
RA   Seki M., Takeda Y., Iwai K., Tanaka K.;
RT   "IOP1 protein is an external component of the human cytosolic iron-sulfur
RT   cluster assembly (CIA) machinery and functions in the MMS19 protein-
RT   dependent CIA pathway.";
RL   J. Biol. Chem. 288:16680-16689(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-505; SER-956; SER-1004 AND
RP   SER-1032, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 985-998 IN COMPLEX WITH BRCA1, AND
RP   SUBUNIT.
RX   PubMed=15125843; DOI=10.1016/s1097-2765(04)00238-2;
RA   Shiozaki E.N., Gu L., Yan N., Shi Y.;
RT   "Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide:
RT   implications for signaling.";
RL   Mol. Cell 14:405-412(2004).
RN   [17]
RP   VARIANTS CYS-173 AND PRO-919.
RX   PubMed=11920628; DOI=10.1002/ijc.10214;
RA   Luo L., Lei H., Du Q., von Wachenfeldt A., Kockum I., Luthman H.,
RA   Vorechovsky I., Lindblom A.;
RT   "No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer
RT   families linked to 17q22.";
RL   Int. J. Cancer 98:638-639(2002).
RN   [18]
RP   VARIANTS PRO-919 AND LEU-1034.
RX   PubMed=12565990; DOI=10.1016/s0959-8049(02)00498-7;
RA   Karppinen S.-M., Vuosku J., Heikkinen K., Allinen M., Winqvist R.;
RT   "No evidence of involvement of germline BACH1 mutations in Finnish breast
RT   and ovarian cancer families.";
RL   Eur. J. Cancer 39:366-371(2003).
RN   [19]
RP   VARIANTS CYS-173; ILE-193; PRO-195; TRP-419; VAL-531; LEU-540; TYR-832;
RP   PRO-919 AND GLY-935.
RX   PubMed=12872252; DOI=10.1002/humu.10238;
RA   Rutter J.L., Smith A.M., Davila M.R., Sigurdson A.J., Giusti R.M.,
RA   Pineda M.A., Doody M.M., Tucker M.A., Greene M.H., Zhang J.,
RA   Struewing J.P.;
RT   "Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and
RT   BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian
RT   cancer families and among early-onset breast cancer cases and reference
RT   individuals.";
RL   Hum. Mutat. 22:121-128(2003).
RN   [20]
RP   VARIANT FANCJ PRO-349.
RX   PubMed=16116424; DOI=10.1038/ng1624;
RA   Levran O., Attwooll C., Henry R.T., Milton K.L., Neveling K., Rio P.,
RA   Batish S.D., Kalb R., Velleuer E., Barral S., Ott J., Petrini J.,
RA   Schindler D., Hanenberg H., Auerbach A.D.;
RT   "The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.";
RL   Nat. Genet. 37:931-933(2005).
RN   [21]
RP   VARIANTS FANCJ HIS-255; CYS-647 AND CYS-707, AND VARIANT TRP-264.
RX   PubMed=16116423; DOI=10.1038/ng1625;
RA   Levitus M., Waisfisz Q., Godthelp B.C., Vries Y., Hussain S., Wiegant W.W.,
RA   Elghalbzouri-Maghrani E., Steltenpool J., Rooimans M.A., Pals G.,
RA   Arwert F., Mathew C.G., Zdzienicka M.Z., Hiom K., De Winter J.P.,
RA   Joenje H.;
RT   "The DNA helicase BRIP1 is defective in Fanconi anemia complementation
RT   group J.";
RL   Nat. Genet. 37:934-935(2005).
RN   [22]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-919.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [23]
RP   VARIANT FANCJ PRO-349, COFACTOR, CHARACTERIZATION OF VARIANT FANCJ PRO-349,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20639400; DOI=10.1182/blood-2009-11-256016;
RA   Wu Y., Sommers J.A., Suhasini A.N., Leonard T., Deakyne J.S., Mazin A.V.,
RA   Shin-Ya K., Kitao H., Brosh R.M. Jr.;
RT   "Fanconi anemia group J mutation abolishes its DNA repair function by
RT   uncoupling DNA translocation from helicase activity or disruption of
RT   protein-DNA complexes.";
RL   Blood 116:3780-3791(2010).
CC   -!- FUNCTION: DNA-dependent ATPase and 5' to 3' DNA helicase required for
CC       the maintenance of chromosomal stability. Acts late in the Fanconi
CC       anemia pathway, after FANCD2 ubiquitination. Involved in the repair of
CC       DNA double-strand breaks by homologous recombination in a manner that
CC       depends on its association with BRCA1. {ECO:0000269|PubMed:11301010,
CC       ECO:0000269|PubMed:14983014, ECO:0000269|PubMed:16116421,
CC       ECO:0000269|PubMed:16153896}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000269|PubMed:20639400};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000269|PubMed:20639400};
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883;
CC         Evidence={ECO:0000269|PubMed:20639400};
CC       Note=Binds 1 [4Fe-4S] cluster. {ECO:0000269|PubMed:20639400};
CC   -!- SUBUNIT: Binds directly to the BRCT domains of BRCA1 (PubMed:15125843).
CC       Interacts with the CIA complex components CIAO1, CIAO2B and MMS19
CC       (PubMed:23585563). {ECO:0000269|PubMed:15125843,
CC       ECO:0000269|PubMed:23585563}.
CC   -!- INTERACTION:
CC       Q9BX63; P54132: BLM; NbExp=16; IntAct=EBI-3509650, EBI-621372;
CC       Q9BX63; P38398: BRCA1; NbExp=28; IntAct=EBI-3509650, EBI-349905;
CC       Q9BX63; Q9BPX1: HSD17B14; NbExp=3; IntAct=EBI-3509650, EBI-742664;
CC       Q9BX63; P40692: MLH1; NbExp=18; IntAct=EBI-3509650, EBI-744248;
CC       Q9BX63; Q96T76: MMS19; NbExp=4; IntAct=EBI-3509650, EBI-1044169;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11301010,
CC       ECO:0000269|PubMed:23585563}. Cytoplasm {ECO:0000269|PubMed:23585563}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BX63-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BX63-2; Sequence=VSP_012540, VSP_012541;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       testis. {ECO:0000269|PubMed:11301010}.
CC   -!- DOMAIN: 4Fe-4S iron-sulfur-binding is required for helicase activity.
CC       {ECO:0000269|PubMed:20639400}.
CC   -!- PTM: Phosphorylated. Phosphorylation is necessary for interaction with
CC       BRCA1, and is cell-cycle regulated. {ECO:0000269|PubMed:14576433}.
CC   -!- PTM: Acetylation at Lys-1249 facilitates DNA end processing required
CC       for repair and checkpoint signaling. {ECO:0000269|PubMed:22792074}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal carcinoma is
CC       by far the most common type. Breast cancer is etiologically and
CC       genetically heterogeneous. Important genetic factors have been
CC       indicated by familial occurrence and bilateral involvement. Mutations
CC       at more than one locus can be involved in different families or even in
CC       the same case. {ECO:0000269|PubMed:11301010,
CC       ECO:0000269|PubMed:14983014}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Fanconi anemia complementation group J (FANCJ) [MIM:609054]: A
CC       disorder affecting all bone marrow elements and resulting in anemia,
CC       leukopenia and thrombopenia. It is associated with cardiac, renal and
CC       limb malformations, dermal pigmentary changes, and a predisposition to
CC       the development of malignancies. At the cellular level it is associated
CC       with hypersensitivity to DNA-damaging agents, chromosomal instability
CC       (increased chromosome breakage) and defective DNA repair.
CC       {ECO:0000269|PubMed:16116423, ECO:0000269|PubMed:16116424,
CC       ECO:0000269|PubMed:20639400}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the DEAD box helicase family. DEAH subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11156.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Fanconi Anemia Mutation Database;
CC       URL="https://www2.rockefeller.edu/fanconi/genes/jumpj";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF360549; AAK38111.1; -; mRNA.
DR   EMBL; AC002994; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005969; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC060798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471179; EAW51430.1; -; Genomic_DNA.
DR   EMBL; CH471179; EAW51432.1; -; Genomic_DNA.
DR   EMBL; CH471179; EAW51431.1; -; Genomic_DNA.
DR   EMBL; CH471179; EAW51433.1; -; Genomic_DNA.
DR   EMBL; BC101472; AAI01473.1; -; mRNA.
DR   EMBL; BC101474; AAI01475.1; -; mRNA.
DR   EMBL; AK074713; BAC11156.1; ALT_INIT; mRNA.
DR   CCDS; CCDS11631.1; -. [Q9BX63-1]
DR   RefSeq; NP_114432.2; NM_032043.2. [Q9BX63-1]
DR   PDB; 1T15; X-ray; 1.85 A; B=988-995.
DR   PDB; 1T29; X-ray; 2.30 A; B=985-998.
DR   PDB; 3AL3; X-ray; 2.15 A; B=1129-1138.
DR   PDBsum; 1T15; -.
DR   PDBsum; 1T29; -.
DR   PDBsum; 3AL3; -.
DR   AlphaFoldDB; Q9BX63; -.
DR   SMR; Q9BX63; -.
DR   BioGRID; 123841; 84.
DR   ComplexPortal; CPX-4426; BRCA1-B complex.
DR   CORUM; Q9BX63; -.
DR   DIP; DIP-41787N; -.
DR   ELM; Q9BX63; -.
DR   IntAct; Q9BX63; 29.
DR   MINT; Q9BX63; -.
DR   STRING; 9606.ENSP00000259008; -.
DR   BindingDB; Q9BX63; -.
DR   GlyGen; Q9BX63; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9BX63; -.
DR   PhosphoSitePlus; Q9BX63; -.
DR   BioMuta; BRIP1; -.
DR   DMDM; 57012613; -.
DR   CPTAC; CPTAC-3220; -.
DR   CPTAC; CPTAC-3221; -.
DR   CPTAC; CPTAC-3222; -.
DR   CPTAC; CPTAC-3281; -.
DR   CPTAC; CPTAC-918; -.
DR   EPD; Q9BX63; -.
DR   jPOST; Q9BX63; -.
DR   MassIVE; Q9BX63; -.
DR   MaxQB; Q9BX63; -.
DR   PaxDb; Q9BX63; -.
DR   PeptideAtlas; Q9BX63; -.
DR   ProteomicsDB; 79352; -. [Q9BX63-1]
DR   ProteomicsDB; 79353; -. [Q9BX63-2]
DR   Antibodypedia; 18594; 355 antibodies from 36 providers.
DR   CPTC; Q9BX63; 5 antibodies.
DR   DNASU; 83990; -.
DR   Ensembl; ENST00000259008.7; ENSP00000259008.2; ENSG00000136492.10. [Q9BX63-1]
DR   Ensembl; ENST00000577598.5; ENSP00000464654.1; ENSG00000136492.10. [Q9BX63-2]
DR   Ensembl; ENST00000682453.1; ENSP00000506943.1; ENSG00000136492.10. [Q9BX63-1]
DR   Ensembl; ENST00000683039.1; ENSP00000508303.1; ENSG00000136492.10. [Q9BX63-1]
DR   GeneID; 83990; -.
DR   KEGG; hsa:83990; -.
DR   MANE-Select; ENST00000259008.7; ENSP00000259008.2; NM_032043.3; NP_114432.2.
DR   UCSC; uc002izk.3; human. [Q9BX63-1]
DR   AGR; HGNC:20473; -.
DR   CTD; 83990; -.
DR   DisGeNET; 83990; -.
DR   GeneCards; BRIP1; -.
DR   GeneReviews; BRIP1; -.
DR   HGNC; HGNC:20473; BRIP1.
DR   HPA; ENSG00000136492; Tissue enhanced (bone marrow, lymphoid tissue, testis).
DR   MalaCards; BRIP1; -.
DR   MIM; 114480; phenotype.
DR   MIM; 605882; gene.
DR   MIM; 609054; phenotype.
DR   neXtProt; NX_Q9BX63; -.
DR   OpenTargets; ENSG00000136492; -.
DR   Orphanet; 84; Fanconi anemia.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   PharmGKB; PA134906421; -.
DR   VEuPathDB; HostDB:ENSG00000136492; -.
DR   eggNOG; KOG1132; Eukaryota.
DR   GeneTree; ENSGT00950000182970; -.
DR   InParanoid; Q9BX63; -.
DR   OMA; FSNDNAR; -.
DR   OrthoDB; 124793at2759; -.
DR   PhylomeDB; Q9BX63; -.
DR   TreeFam; TF329449; -.
DR   BRENDA; 3.6.4.12; 2681.
DR   PathwayCommons; Q9BX63; -.
DR   Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function.
DR   Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function.
DR   Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function.
DR   Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51.
DR   Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2.
DR   SignaLink; Q9BX63; -.
DR   SIGNOR; Q9BX63; -.
DR   BioGRID-ORCS; 83990; 108 hits in 1165 CRISPR screens.
DR   ChiTaRS; BRIP1; human.
DR   EvolutionaryTrace; Q9BX63; -.
DR   GeneWiki; BRIP1; -.
DR   GenomeRNAi; 83990; -.
DR   Pharos; Q9BX63; Tbio.
DR   PRO; PR:Q9BX63; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9BX63; protein.
DR   Bgee; ENSG00000136492; Expressed in ventricular zone and 125 other tissues.
DR   ExpressionAtlas; Q9BX63; baseline and differential.
DR   Genevisible; Q9BX63; HS.
DR   GO; GO:0070532; C:BRCA1-B complex; IPI:ComplexPortal.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0043139; F:5'-3' DNA helicase activity; IDA:HGNC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0003678; F:DNA helicase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071295; P:cellular response to vitamin; IEA:Ensembl.
DR   GO; GO:0051026; P:chiasma assembly; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; NAS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; NAS:ComplexPortal.
DR   GO; GO:0006302; P:double-strand break repair; NAS:UniProtKB.
DR   GO; GO:1990918; P:double-strand break repair involved in meiotic recombination; IBA:GO_Central.
DR   GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal.
DR   GO; GO:0010705; P:meiotic DNA double-strand break processing involved in reciprocal meiotic recombination; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006289; P:nucleotide-excision repair; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0007284; P:spermatogonial cell division; IEA:Ensembl.
DR   CDD; cd17970; DEAHc_FancJ; 1.
DR   CDD; cd18788; SF2_C_XPD; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 3.
DR   IDEAL; IID00181; -.
DR   InterPro; IPR006555; ATP-dep_Helicase_C.
DR   InterPro; IPR010614; DEAD_2.
DR   InterPro; IPR045028; DinG/Rad3-like.
DR   InterPro; IPR014013; Helic_SF1/SF2_ATP-bd_DinG/Rad3.
DR   InterPro; IPR006554; Helicase-like_DEXD_c2.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013020; Rad3/Chl1-like.
DR   PANTHER; PTHR11472; DNA REPAIR DEAD HELICASE RAD3/XP-D SUBFAMILY MEMBER; 1.
DR   PANTHER; PTHR11472:SF47; FANCONI ANEMIA GROUP J PROTEIN; 1.
DR   Pfam; PF06733; DEAD_2; 1.
DR   Pfam; PF13307; Helicase_C_2; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00488; DEXDc2; 1.
DR   SMART; SM00491; HELICc2; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS51193; HELICASE_ATP_BIND_2; 1.
DR   TIGRFAMs; TIGR00604; rad3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; 4Fe-4S; Acetylation; Alternative splicing; ATP-binding;
KW   Cytoplasm; Direct protein sequencing; Disease variant; DNA damage;
KW   DNA repair; Fanconi anemia; Helicase; Hydrolase; Iron; Iron-sulfur;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..1249
FT                   /note="Fanconi anemia group J protein"
FT                   /id="PRO_0000055173"
FT   DOMAIN          11..442
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   REGION          102..131
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          888..1063
FT                   /note="Interaction with BRCA1"
FT                   /evidence="ECO:0000269|PubMed:11301010"
FT   REGION          1018..1042
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1108..1127
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           158..175
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           393..396
FT                   /note="DEAH box"
FT   COMPBIAS        1022..1036
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1108..1126
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         185..192
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   BINDING         283
FT                   /ligand="[4Fe-4S] cluster"
FT                   /ligand_id="ChEBI:CHEBI:49883"
FT                   /evidence="ECO:0000250"
FT   BINDING         298
FT                   /ligand="[4Fe-4S] cluster"
FT                   /ligand_id="ChEBI:CHEBI:49883"
FT                   /evidence="ECO:0000250"
FT   BINDING         310
FT                   /ligand="[4Fe-4S] cluster"
FT                   /ligand_id="ChEBI:CHEBI:49883"
FT                   /evidence="ECO:0000250"
FT   BINDING         350
FT                   /ligand="[4Fe-4S] cluster"
FT                   /ligand_id="ChEBI:CHEBI:49883"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         505
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         927
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         930
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         956
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         990
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14576433,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         1004
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1032
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1237
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1249
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22792074"
FT   VAR_SEQ         969..994
FT                   /note="NDPVFLEEAGKAEKIVISRSTSPTFN -> SMKSSSHLPLIEKSFIIFSEMI
FT                   FIWV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012540"
FT   VAR_SEQ         995..1249
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012541"
FT   VARIANT         47
FT                   /note="P -> A (in BC; early onset; loss of ATPase and
FT                   helicase activities; dbSNP:rs28903098)"
FT                   /evidence="ECO:0000269|PubMed:11301010,
FT                   ECO:0000269|PubMed:14983014"
FT                   /id="VAR_020896"
FT   VARIANT         173
FT                   /note="R -> C (in dbSNP:rs4988345)"
FT                   /evidence="ECO:0000269|PubMed:11920628,
FT                   ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020897"
FT   VARIANT         193
FT                   /note="V -> I (in dbSNP:rs4988346)"
FT                   /evidence="ECO:0000269|PubMed:11301010,
FT                   ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020898"
FT   VARIANT         195
FT                   /note="L -> P (in dbSNP:rs4988347)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020899"
FT   VARIANT         255
FT                   /note="Q -> H (in FANCJ)"
FT                   /evidence="ECO:0000269|PubMed:16116423"
FT                   /id="VAR_023700"
FT   VARIANT         264
FT                   /note="R -> W (in dbSNP:rs28997569)"
FT                   /evidence="ECO:0000269|PubMed:16116423"
FT                   /id="VAR_023701"
FT   VARIANT         299
FT                   /note="M -> I (in BC; early onset; reduces helicase
FT                   efficiency on longer substrates; dbSNP:rs137852985)"
FT                   /evidence="ECO:0000269|PubMed:11301010,
FT                   ECO:0000269|PubMed:14983014"
FT                   /id="VAR_020900"
FT   VARIANT         349
FT                   /note="A -> P (in FANCJ; destabilizes iron-sulfur-binding
FT                   and abolishes helicase activity; dbSNP:rs149364097)"
FT                   /evidence="ECO:0000269|PubMed:16116424,
FT                   ECO:0000269|PubMed:20639400"
FT                   /id="VAR_023702"
FT   VARIANT         419
FT                   /note="R -> W (in dbSNP:rs150624408)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020901"
FT   VARIANT         531
FT                   /note="F -> V (in dbSNP:rs4988350)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020902"
FT   VARIANT         540
FT                   /note="Q -> L (in dbSNP:rs4988349)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020903"
FT   VARIANT         633
FT                   /note="I -> M (in dbSNP:rs28997572)"
FT                   /id="VAR_052192"
FT   VARIANT         647
FT                   /note="W -> C (in FANCJ; associated with C-707;
FT                   dbSNP:rs786202760)"
FT                   /evidence="ECO:0000269|PubMed:16116423"
FT                   /id="VAR_023703"
FT   VARIANT         707
FT                   /note="R -> C (in FANCJ; associated with C-647;
FT                   dbSNP:rs764803896)"
FT                   /evidence="ECO:0000269|PubMed:16116423"
FT                   /id="VAR_023704"
FT   VARIANT         832
FT                   /note="C -> Y (in dbSNP:rs4988355)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020904"
FT   VARIANT         919
FT                   /note="S -> P (in dbSNP:rs4986764)"
FT                   /evidence="ECO:0000269|PubMed:11301010,
FT                   ECO:0000269|PubMed:11920628, ECO:0000269|PubMed:12565990,
FT                   ECO:0000269|PubMed:12872252, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:16153896, ECO:0000269|PubMed:18987736"
FT                   /id="VAR_020905"
FT   VARIANT         935
FT                   /note="V -> G (in dbSNP:rs4988356)"
FT                   /evidence="ECO:0000269|PubMed:12872252"
FT                   /id="VAR_020906"
FT   VARIANT         1034
FT                   /note="P -> L (in a patient with ovarian cancer; unknown
FT                   pathological significance; dbSNP:rs1199923024)"
FT                   /evidence="ECO:0000269|PubMed:12565990"
FT                   /id="VAR_020907"
FT   VARIANT         1148
FT                   /note="D -> E (in dbSNP:rs28997573)"
FT                   /id="VAR_052193"
FT   MUTAGEN         52
FT                   /note="K->R: Disrupts BRCA1-mediated double-strand break
FT                   repair. Loss of ATPase and DNA helicase activities."
FT                   /evidence="ECO:0000269|PubMed:11301010,
FT                   ECO:0000269|PubMed:14983014, ECO:0000269|PubMed:16116421"
FT   MUTAGEN         986
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         988
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         989
FT                   /note="T->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         990
FT                   /note="S->A: Disrupts the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         991
FT                   /note="P->A: Abolishes phosphorylation of S-990. Impairs
FT                   the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         992
FT                   /note="T->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         993
FT                   /note="F->A: Abolishes phosphorylation of S-990. Impairs
FT                   the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         997
FT                   /note="T->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1001
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1003
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1004
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1007
FT                   /note="S->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1011
FT                   /note="Y->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   MUTAGEN         1013
FT                   /note="T->A: Does not affect the interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:14576433"
FT   CONFLICT        641
FT                   /note="I -> V (in Ref. 5; BAC11156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        767
FT                   /note="E -> I (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1249 AA;  140867 MW;  8ED691F03A442BE1 CRC64;
     MSSMWSEYTI GGVKIYFPYK AYPSQLAMMN SILRGLNSKQ HCLLESPTGS GKSLALLCSA
     LAWQQSLSGK PADEGVSEKA EVQLSCCCAC HSKDFTNNDM NQGTSRHFNY PSTPPSERNG
     TSSTCQDSPE KTTLAAKLSA KKQASIYRDE NDDFQVEKKR IRPLETTQQI RKRHCFGTEV
     HNLDAKVDSG KTVKLNSPLE KINSFSPQKP PGHCSRCCCS TKQGNSQESS NTIKKDHTGK
     SKIPKIYFGT RTHKQIAQIT RELRRTAYSG VPMTILSSRD HTCVHPEVVG NFNRNEKCME
     LLDGKNGKSC YFYHGVHKIS DQHTLQTFQG MCKAWDIEEL VSLGKKLKAC PYYTARELIQ
     DADIIFCPYN YLLDAQIRES MDLNLKEQVV ILDEAHNIED CARESASYSV TEVQLRFARD
     ELDSMVNNNI RKKDHEPLRA VCCSLINWLE ANAEYLVERD YESACKIWSG NEMLLTLHKM
     GITTATFPIL QGHFSAVLQK EEKISPIYGK EEAREVPVIS ASTQIMLKGL FMVLDYLFRQ
     NSRFADDYKI AIQQTYSWTN QIDISDKNGL LVLPKNKKRS RQKTAVHVLN FWCLNPAVAF
     SDINGKVQTI VLTSGTLSPM KSFSSELGVT FTIQLEANHI IKNSQVWVGT IGSGPKGRNL
     CATFQNTETF EFQDEVGALL LSVCQTVSQG ILCFLPSYKL LEKLKERWLS TGLWHNLELV
     KTVIVEPQGG EKTNFDELLQ VYYDAIKYKG EKDGALLVAV CRGKVSEGLD FSDDNARAVI
     TIGIPFPNVK DLQVELKRQY NDHHSKLRGL LPGRQWYEIQ AYRALNQALG RCIRHRNDWG
     ALILVDDRFR NNPSRYISGL SKWVRQQIQH HSTFESALES LAEFSKKHQK VLNVSIKDRT
     NIQDNESTLE VTSLKYSTSP YLLEAASHLS PENFVEDEAK ICVQELQCPK IITKNSPLPS
     SIISRKEKND PVFLEEAGKA EKIVISRSTS PTFNKQTKRV SWSSFNSLGQ YFTGKIPKAT
     PELGSSENSA SSPPRFKTEK MESKTVLPFT DKCESSNLTV NTSFGSCPQS ETIISSLKID
     ATLTRKNHSE HPLCSEEALD PDIELSLVSE EDKQSTSNRD FETEAEDESI YFTPELYDPE
     DTDEEKNDLA ETDRGNRLAN NSDCILAKDL FEIRTIKEVD SAREVKAEDC IDTKLNGILH
     IEESKIDDID GNVKTTWINE LELGKTHEIE IKNFKPSPSK NKGMFPGFK
//
